Immunocore Is the Latest to Nab a Private Placement, Securing $140M to Pursue More TCR R&D

Look­ing to se­cure a fresh raise to in­vig­o­rate R&D, Im­muno­core is putting to­geth­er a PIPE.

The for­mer Medi­gene spin­out, six months af­ter the FDA ap­proved its TCR drug tebenta­fusp, put out word Mon­day that it’s sell­ing just over 3.7 mil­lion shares of com­pa­ny stock at $37.50 each. This is go­ing to cer­tain in­vestors as a PIPE fi­nanc­ing for a to­tal of $140 mil­lion.

Read the full article at: endpts.com

• About the Author
• Latest Posts

BioBuzz Media

BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.

• BHI Welcomes Three New Members to its Board of Directors
• In Conversation with Michael Riotto, Myeloma Coach, The HealthTree Foundation
• In Conversation with Denita Henderson, Managing Director, Pennovation Works